Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL2588291 | 1.00 | NOS2 (0.39) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL3519300 | 1.00 | NOS2 (0.39) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL27957063 | 1.00 | NOS2 (0.39) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL285829 | 1.00 | NOS2 (0.39) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL140697 | 1.00 | NOS2 (0.39) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL140699 | 1.00 | NOS2 (0.39) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL515538 | 0.94 | NOS2 (0.35) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL27413727 | 0.94 | NOS2 (0.35) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL3100837 | 0.94 | NOS2 (0.35) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL181143 | 0.94 | NOS2 (0.35) | NOS2NOS3NOS1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023131707-A1 | STABILIZING N-CAP SEQUENCES FOR ARMADILLO REPEAT PROTEINS | Universität Zürich (CH) | 2023-07-13 | — | — | WO | claimed |
| CN-115197952-A | Mutant gene of rice waxy gene Wx and application thereof | 重庆市农业科学院 | 2022-10-18 | — | — | CN | claimed |
| EP-2528581-B1 | METHOD AND COMPOSITIONS FOR THE APPLICATION OF AMINO ACIDS ON THE SKIN THROUGH AN ANHYDROUS MEAN | AMBROSIALAB S R L (IT) | 2019-11-06 | — | — | EP | claimed |
| CN-108771168-A | A kind of cucumber peel preparation method | 广西博白县众旺农产品专业合作社 | 2018-11-09 | — | — | CN | claimed |
| EP-2528581-A2 | METHOD AND COMPOSITIONS FOR THE APPLICATION OF AMINO ACIDS ON THE SKIN THROUGH AN ANHYDROUS MEAN | Ambrosialab S.r.L. (IT) | 2012-12-05 | — | — | EP | claimed |
| WO-2011092581-A2 | METHOD AND COMPOSITIONS FOR THE APPLICATION OF AMINO ACIDS ON THE SKIN THROUGH AN ANHYDROUS MEAN | AMBROSIALAB S.R.L. (IT) | 2011-08-04 | — | — | WO | claimed |
| US-20110178000-A1 | Apoptotically Active Peptides | CYTOTOOLS AG (DE) | 2011-07-21 | — | — | US | claimed |
| US-5905142-A | Protease resistant PDGF and methods of use | ZYMOGENETICS, INC. (US) | 1999-05-18 | — | — | US | claimed |
| CN-115297717-B | Barley plants with high limit dextrinase activity | 嘉士伯有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20240139259-A1 | ENZYME AND PROBIOTICS TAKEN WITH PROTEIN, CREATE A WHOLISTIC SYSTEM THAT PREVENTS THE NEGATIVE EFFECTS OF PROTEIN INDIGESTION ON GUT MICROBIOTA, PROMOTE MICROFLORA BALANCE, AND INCREASE THE BIOAVAILABILITY OF POSTBIOTICS | ADVANCED ENZYME TECHNOLOGIES LTD. (IN) | 2024-05-02 | — | — | US | disclosed |
| WO-2024079433-A1 | PMHC-BINDING HETERODIMERIC RECEPTORS WITH AN IMPROVED DISCRIMINATION BETWEEN A LOW AFFINITY AND A HIGH AFFINITY PMHC AND THAT DO NOT ASSOCIATED WITH CD3 | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-04-18 | — | — | WO | disclosed |
| CN-114573661-B | Small molecular peptide and application thereof in promoting transdermal absorption of biomacromolecules | 冯来坤 | 2023-10-27 | — | — | CN | disclosed |
| US-20230270876-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| WO-2023131707-A1 | STABILIZING N-CAP SEQUENCES FOR ARMADILLO REPEAT PROTEINS | Universität Zürich (CH) | 2023-07-13 | — | — | WO | disclosed |
| WO-2000036112-A1 | MUTANTS OF RNA POLYMERASES WITH INCREASED STABILITY | AKZO NOBEL N.V. (NL) | 2000-06-22 | — | — | WO | disclosed |
| WO-1999037770-A1 | PHAGOCYTOSIS GENES AND USES THEREOF | COLD SPRING HARBOR LABORATORY (US) | 1999-07-29 | — | — | WO | disclosed |
| EP-0576669-A4 | NOVEL METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISEASES | REPLIGEN CORP (US) | 1996-05-08 | — | — | EP | disclosed |
| EP-0576669-A1 | NOVEL METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISEASES | REPLIGEN CORPORATION (US) | 1994-01-05 | — | — | EP | disclosed |
| WO-1993013794-A1 | NOVEL METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISEASES | REPLIGEN CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
| US-4914129-A | Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups | CIBA-GEIGY CORPORATION (US) | 1990-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270876-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | PTMS, FCGR2A, FCGR3B | NOS2 4527/4885NOS3 4571/4885NOS1 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.